Elles se sont fait attendre ces connes mais elles sont sympas (ce n'est pas un poisson d'avril elle date du 21 mars)
Voila un passage bien cool
"Although the small study size precluded statistical demonstration of treatment effects, the analyses
showed a favorable impact of temelimab in preserving neocortical anatomy and myelin integrity. The
effect sizes were of comparable magnitude to those previously observed in the CHANGE-MS and
ANGEL-MS trials. The combined treatment of temelimab and rituximab protected against loss of cortical
thickness by more than 50% relative to rituximab alone. Furthermore, cortical tissue integrity, as
measured by magnetization transfer saturation, was improved with temelimab, potentially reflecting
remyelination."
Et l'annonce complete de geneuro
http://www.geneuro.com/data/news/GeNeur ... 1-2022.pdf